Trojan horses encapsulated by a TRODELVYᵀᴹ cell membrane in a green, cellular environment.

Results 

In adults with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor*

Nearly 30% of patients responded to TREATMENT WITH TRODELVY1

Overall Response Rate (ORR) by IRA based on RECIST 1.1

TRODELVY® (sacituzumab govitecan-hziy) Overall Response Rate Chart

Median Duration of Response (DOR) by IRA based on RECIST 1.1

TRODELVY® (sacituzumab govitecan-hziy) Duration of Response Chart

*TRODELVY is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1

Based on a phase 2, single-arm, open-label, multicenter trial (N=112). See study design for more information.

IRA=independent review assessment; RECIST=Response Evaluation Criteria in Solid Tumors.

Reference: 1. TRODELVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2021.